Articles

Find an Article

Filter articles

Showing 1 to 10 of 432 results

IP strategy: when sharing is caring

Germany, International22-06-2017

Collaboration and sharing are important goals for Bayer in seeking to protect innovations with IP rights, as Richard Rees explains in an interview with LSIPR.

Bated breath: awaiting the Amgen v Sandoz verdict

US21-06-2017

With the US Supreme Court set to decide the biosimilars dispute between Amgen and Sandoz, LSIPR examines the possible outcomes and implications for those in the industry.

Navigating medical use in Japan

Japan21-06-2017

A handful of high-profile disputes over medical use patents have been decided in Japan, as Osamu Yamamoto of Yuasa and Hara reports.

Life sciences regulation in India: the need for evolution

India15-06-2017Kirit Javali

India’s regulatory environment surrounding pharmaceuticals and medical devices needs to evolve in order to unlock the industries’ true potential, says Kirit Javali of Jafa & Javali.

Medical devices new rules: the clock is ticking

EU13-06-2017Jo Emmett

A new EU regulation on implantable medical devices takes steps to acknowledge that patient outcomes and safety are primary goals, but the transition to the new system might not be easy for industry stakeholders, says Jo Emmett of Premier Research.

Patent examination in Brazil: go green to beat the backlog

Brazil13-06-2017

The Brazilian Patent and Trademark Office has implemented several fast-track examination programmes. Ana Paula Jardim and Andréa Granthon of Luiz Leonardos report on the effectiveness of one of them, the Green Patent Programme.

Machine learning: new discoveries and challenges for life sciences

07-06-2017Erica Pascal

Erica Pascal of DLA Piper investigates the patentability of machine learning and its outcomes, and the complex issues that may arise.

Levelling the SPC playing field

EU19-05-2017Allison Sadick

Medical technology companies should not be left out of discussions in Europe about modernising the system for supplementary protection certificates, argues Allison Sadick of Pinsent Masons.

ANVISA and INPI: the end of an impasse?

Brazil25-04-2017Breno Souza, Luisa Rezende and Silvia Costa

A disagreement over how pharma patents in Brazil are examined seems to have come to an end, as Breno Souza, Luisa Rezende and Silvia Costa of Clarke Modet & Co Brazil report.

Plants, patents and political challenges

EU04-04-2017Jane Wainwright

European developments surrounding the patentability of plants and animals have become rather political, but there are ways for patentees to mitigate the effects of political influence over the patenting process, writes Jane Wainwright of Potter Clarkson.

Showing 1 to 10 of 432 results

LSIPR